Analyst firms · BofA Securities · ESPR

BofA Securities ESPR price target and rating history

Esperion Therapeutics Inc. (ESPR) · Health Care

BofA Securities rates Esperion Therapeutics Inc. (ESPR) Underperform with a $2.50 price target, as of its latest action on Jun 20, 2024. It has published 5 rating actions on ESPR since February 2023, including 1 upgrade and 3 downgrades.

Current rating
Underperform
Price target
$2.50
Median target, all firms
Too few
Actions on ESPR
5

BofA Securities price target on ESPR

$8$4.75$1.50202420252026
BofA Securities price target on ESPR, each point a stated target, February 2023 to June 2024.

Every BofA Securities rating on ESPR

How other firms rate ESPR

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightNeutralMay 1, 2026
Piper SandlerOverweight$9Nov 25, 2025

Questions about BofA Securities and ESPR

What is BofA Securities's price target for ESPR?
BofA Securities's latest stated price target for Esperion Therapeutics Inc. (ESPR) is $2.50, from its action on Jun 20, 2024.
What is BofA Securities's rating on ESPR?
BofA Securities rates ESPR Underperform, a bearish rating, as of Jun 20, 2024.
When did BofA Securities last change its view on ESPR?
On Jun 20, 2024, BofA Securities downgrades to Underperform from Neutral, price target $2.50.

More ESPR rating histories

All BofA Securities ratingsESPR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.